3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
215
Rectal Neoplasms
85
Colonic Neoplasms
76
Stomach Neoplasms
56
Pancreatic Neoplasms
44
Neoplasm Metastasis
40
Esophageal Neoplasms
37
Neoplasms
28
Lung Neoplasms
27
Carcinoma, Non-Small-Cell Lung
20
Small Cell Lung Carcinoma
19
Adenocarcinoma Of Esophagus
19
Glioblastoma
18
Glioma
17
Neuroblastoma
16
Esophageal Squamous Cell Carcinoma
16
Brain Neoplasms
16
Breast Neoplasms
15
Sarcoma
11
Gliosarcoma
10
Biliary Tract Neoplasms
10
Central Nervous System Neoplasms
9
Astrocytoma
8
Adenocarcinoma
8
Oligodendroglioma
7
Medulloblastoma
7
Colorectal Cancer Metastatic
7
Rhabdomyosarcoma
6
Recurrence
6
Locally Advanced Rectal Cancer
6
Interventions
Trastuzumab
5
Carboplatin
4
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
Irinotecan
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled